Evidence map›Paper›PMID 37064334›Full record

ArticleMolecular syndromology2023

Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society.

Eric D Hamlett, Lisi Flores-Aguilar, Benjamin Handen, Marie-Claude Potier, Ann-Charlotte Granholm, Stephanie Sherman, Victoria Puig, Jonathan D Santoro, María Carmona-Iragui, Anne-Sophie Rebillat and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular syndromology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 5 countries.

Eric D HamlettDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Lisi Flores-AguilarDepartment of Anatomy and Cell Biology, McGill University, Montreal, Québec, Canada.
Benjamin HandenDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Marie-Claude PotierParis Brain Institute, ICM, Pitié-Salpêtrière Hospital, Paris, France.
Ann-Charlotte GranholmDepartment of Neurosurgery, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA.
Stephanie ShermanDepartment of Human Genetics, Emory University, Atlanta, Georgia, USA.
Victoria PuigCatalan Institute of Nanoscience and Nanotechnology, Barcelona, Spain.
Jonathan D SantoroNeurological Institute, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
María Carmona-IraguiHospital de la Santa Crue I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Anne-Sophie RebillatInstitut Jérôme Lejeune, Paris, France.
Elizabeth HeadDepartment of Pathology and Laboratory Medicine, University of California, Irvine, California, USA.
André StrydomInstitute of Psychiatry, King's College London, London, UK.
Jorge BusciglioNeurobiology and Behavior School of Biological Sciences, University of California, Irvine, California, USA.
University of California, Irvine · USEmory University · USFondation Jérôme-Lejeune · FRInstitut Català de Nanociència i Nanotecnologia · ESKing's College London · GBMedical University of South Carolina · USSorbonne Université · FRUniversitat Autònoma de Barcelona · ESUniversity of Colorado Anschutz Medical Campus · USUniversity of Pittsburgh · USUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research focused on Down syndrome continued to gain momentum in the last several years and is advancing our understanding of how trisomy 21 (T21) modifies molecular and cellular processes. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. During the COVID pandemic, T21RS held its first virtual conference program, sponsored by the University of California at Irvine, on June 8-10, 2021 and brought together 342 scientists, families, and industry representatives from over 25 countries to share the latest discoveries on underlying cellular and molecular mechanisms of T21, cognitive and behavioral changes, and comorbidities associated with Down syndrome, including Alzheimer's disease and Regression Disorder. Presentations of 91 cutting-edge abstracts reflecting neuroscience, neurology, model systems, psychology, biomarkers, and molecular and pharmacological therapeutic approaches demonstrate the compelling interest and continuing advancement toward innovating biomarkers and therapies aimed at ameliorating health conditions associated with T21.

Indexed as

BiomarkersClinical researchDown syndromeIntellectual disabilityPreclinical research

Identifiers

PMID37064334
PMCPMC10090974
OpenAlexW4308789228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.